Guangdong Hybribio Biotech Co Ltd
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-tim… Read more
Guangdong Hybribio Biotech Co Ltd (300639) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.018x
Based on the latest financial reports, Guangdong Hybribio Biotech Co Ltd (300639) has a cash flow conversion efficiency ratio of 0.018x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥66.39 Million) by net assets (CN¥3.73 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Guangdong Hybribio Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Guangdong Hybribio Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Guangdong Hybribio Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guangdong Hybribio Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RENEW ENG.GLB.A DL-0001
F:7JU
|
N/A |
|
Tianjin Saixiang Technology Co Ltd
SHE:002337
|
0.025x |
|
UCO Bank
NSE:UCOBANK
|
0.060x |
|
Hunan Chen Dian International Development Co Ltd
SHG:600969
|
0.109x |
|
Silence Therapeutics PLC
NASDAQ:SLN
|
-0.147x |
|
Hopson Development Holdings Limited
PINK:HPDHF
|
0.045x |
|
Skjern Bank A/S
CO:SKJE
|
0.007x |
|
Jiangsu High Hope International Group Corp
SHG:600981
|
-0.061x |
Annual Cash Flow Conversion Efficiency for Guangdong Hybribio Biotech Co Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Guangdong Hybribio Biotech Co Ltd from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥4.05 Billion | CN¥78.78 Million | 0.019x | -68.94% |
| 2023-12-31 | CN¥5.10 Billion | CN¥319.60 Million | 0.063x | -74.98% |
| 2022-12-31 | CN¥5.23 Billion | CN¥1.31 Billion | 0.250x | +37.87% |
| 2021-12-31 | CN¥3.48 Billion | CN¥631.34 Million | 0.182x | +47.91% |
| 2020-12-31 | CN¥2.53 Billion | CN¥311.30 Million | 0.123x | +28.97% |
| 2019-12-31 | CN¥1.18 Billion | CN¥112.83 Million | 0.095x | +27.97% |
| 2018-12-31 | CN¥1.08 Billion | CN¥80.39 Million | 0.074x | -8.72% |
| 2017-12-31 | CN¥970.90 Million | CN¥79.17 Million | 0.082x | -35.72% |
| 2016-12-31 | CN¥501.67 Million | CN¥63.63 Million | 0.127x | +8.26% |
| 2015-12-31 | CN¥413.71 Million | CN¥48.47 Million | 0.117x | +16.51% |
| 2014-12-31 | CN¥344.60 Million | CN¥34.65 Million | 0.101x | -15.93% |
| 2013-12-31 | CN¥191.38 Million | CN¥22.89 Million | 0.120x | -3.12% |
| 2012-12-31 | CN¥130.29 Million | CN¥16.08 Million | 0.123x | -- |